Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With Everolimus and Enteric-coated Mycophenolate Sodium or a CNI Based Regimen With Cyclosporine and Enteric-coated Mycophenolate Sodium.

Trial Profile

Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With Everolimus and Enteric-coated Mycophenolate Sodium or a CNI Based Regimen With Cyclosporine and Enteric-coated Mycophenolate Sodium.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational
  • Acronyms CERTITEM
  • Sponsors Novartis
  • Most Recent Events

    • 04 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Interim results presented at the 24th International Congress of the Transplantation Society.
    • 30 Apr 2012 Planned end date (Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top